Tag: head and neck

Keytruda extends survival in first-line head and neck cancer trial

by Selina McKee | Jul 25, 2018 | News | 0

MSD’s Keytruda significantly extended overall survival when used as monotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients expressing PD-L1.

FDA clears Opdivo for head and neck cancer

by Selina McKee | Nov 11, 2016 | News | 0

Bristol-Myers Squibb’s Opdivo has become the first immuno-oncology therapy to win US Food and Drug Administration approval for head and neck cancer.

CERo reports encouraging early data from phase 1 trial of CER‑1236
ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
Argo Biopharma doses first patient in phase 2b trial of BW‑20829
Akari files new patent and advances second ADC targeting CEACAM5
BioMed X launches kidney disease project in partnership with the government of Barbados

PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN

E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999

Tag: head and neck

Keytruda extends survival in first-line head and neck cancer trial

FDA clears Opdivo for head and neck cancer

News alerts

Latest content

Contact details

Download our apps

Content

Connect

Legal